Brief: Saluda Medical Sees FY27 Revenue Growth Between 25% And 35% Versus FY26
28/08/2026 02:39
BRIEF-Saluda Medical Sees FY27 Revenue Growth Between 25% And 35% Versus FY26 Aug 28 (Reuters) - Saluda Medical Inc SLD.AX:
SEES FY27 REVENUE GROWTH BETWEEN 25% AND 35% VERSUS FY26
SEES FY27 ADJUSTED EBITDA LOSS BETWEEN US$101 MILLION AND US$95 MILLION
SEES FY27 GROSS MARGIN 50% TO 52%
Further company coverage: SLD.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Saluda Medical
See all newsBrief: Saluda Medical Initiates Voluntary Field Action For Certain Evoke® System Devices
Saluda Medical's shares hit record low on Evoke device recall
Australia's Saluda Medical hits record low on voluntary device field action
Brief: Saluda Medical Expands Access To FDA-Approved Closed-Loop Surgical Paddle Lead
Brief: Saluda Medical Appoints Mike Mathias As CEO Replacing Barry Regan